[1]
Sing, N.; Das, P.; Gupta, S.; Sachdev, V.; Srivasatava, S.; Gupta, S.D.; Pandey, R.M.; Sahni, P.; Chauhan, S.S.; Saraya, A. Plasma cathepsin L: A prognostic marker for pancreatic cancer. World J. Gastroenterol., 2014, 46, 17532-1750.
[2]
Herman, J.M.; Regine, W.F. Adjuvant pancreatic cancer therapy: No one should go it alone or be left behind. Int. J. Radiat. Oncol. Biol. Phys., 2010, 3, 645-657.
[3]
Postlewait, L.M.; Ethun, C.G.; Kooby, D.A.; Sarmiento, J.M.; Chen, Z.; Staley, C.A.; Brutcher, E.; Adsay, V.; El-Rayes, B.; Maithel, S.K. Combination gemcitabin/cisplatin therapy and ERCC1 expression for resected pancreatic adenocarcinoma: Results of a phase II prospective trial. J. Surg. Oncol., 2016, 114, 336-341.
[4]
Fahrioglu, U.; Dodurga, Y.; Elmas, L.; Seçme, M. Ferulic acid decreases cell viability and colony formation while inhibiting migration of MIA Paca-2 human pancreatic cancer cells in vitro. Gene, 2016, 576, 476-482.
[5]
Mehrara, E.; Forssell-Aronsoon, E.; Bernhardt, P. Objective assessment of tumour response to therapy based on tumour growth kinetics. Br. J. Cancer, 2011, 105, 682-686.
[6]
Millar, A.W.; Lynch, K.P. Rethinking clinical trials for cytostatic drugs. Nat. Rev. Cancer, 2003, 7, 540-545.
[7]
Balzarini, J.; Ostrowski, T.; Goslinski, T.; Clercq, E.D.; Golankiewicz, B. Pronounced cytostatic activity and bystander effect of a novel series of fluorescent tricyclic acyclovir and ganciclovir derivatives in herpes simplex virus thymidine kinase gene-transduced tumor cell lines. Gene Ther., 2002, 9, 1173-1182.
[8]
Pisanu, M.E.; Ricci, A.; Paris, L.; Surrentino, E.; Liliac, L.; Bagnoli, M.; Canevari, S.; Mezzanzanica, D.; Podo, F.; Iorio, E.; Canese, R. Monitoring response to cytostatic cisplatin in a HER2(+) ovary cancer model by MRI and in vitro and in vivo MR spectroscopy. Br. J. Cancer, 2014, 110, 625-635.
[9]
Yamamoto, J.; Ohnuma, K.; Hatano, R.; Okamoto, T.; Komiya, E.; Yamazaki, H.; Iwata, S.; Dang, N.H.; Aoe, K.; Kishimito, T.; Yamada, T.; Morimoto, C. Regulation of somatostatin receptor 4-mediated cytostatic effects by CD26 in malignant pleural mesothelioma. Br. J. Cancer, 2014, 110, 2232-2245.
[10]
Schneider, N.F.Z.; Persich, L.; Rocha, S.C.; Ramos, A.C.P.; Cortes, V.F.; Silva, I.T.; Munkert, J.; Pádua, R.M.; Kreis, W.; Taranto, A.G.; Barbosa, L.A.; Braga, F.C.; Simões, C.M.O. Cytotoxic and cytostatic effects of digitoxigenin monodigitoxide (DGX) in human lung cancer cells and its link to Na,K-ATPase. Biomed. Pharmacother., 2018, 97, 684-696.
[11]
Olson, O.C.; Joyce, J.A. Cysteine cathepsin proteases: regulators of cancer progression and therapeutic response. Nat. Rev. Cancer, 2015, 12, 712-729.
[12]
Siklos, M.; BenAisssa, M.; Thatcher, G.R.J. Cysteine proteases as therapeutic target: does selectivity matter? A systematic review of calpain and cathepsin inhibitors. Acta Pharm. Sin. B, 2015, 6, 506-529.
[13]
Wilkinson, R.D.A.; Young, A.; Burden, R.E.; Williams, R.; Scott, C.J. A bioavailable cathepsin S nitrile inhibitor abrogates tumor development. Mol. Cancer, 2016, 15, 29.
[14]
Foucquier, J.; Guedj, M. Analysis of drug combination: current methodological landscape. Pharmacol. Res. Perspect., 2015, 3, e00149.
[15]
Awasthi, N.; Zhang, C.; Schwarz, A.M.; Hinz, S.; Wang, C.; Williams, N.S.; Schwarz, A.S.; Schwarz, R.E. Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer. Carcinogenesis, 2013, 10, 2361-2369.
[16]
Saidel, M.É.; dos Santos, K.C.; Nagano, L.F.P.; Montanari, C.A.; Leitão, A. Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway. Bioorg. Med. Chem. Lett., 2017, 27, 4001-4006.
[17]
Caroselli, E.E.; Assis, D.M.; Barbiéri, C.L.; Júdice, W.A.S.; Juliano, M.A.; Gazarini, M.L.; Juliano, L. Leishmania (L.) amazonensis peptidase activities inside the living cells and in their lysates. Mol. Biochem. Parasitol., 2012, 184, 82-89.
[18]
Avelar, L.A.A.; Camilo, C.D.; Albuquerque, S.; Fernandes, W.B.; Gonçalez, C.; Kenny, P.W.; Leitão, A.; McKerrow, J.H.; Montanari, C.A.; Orozco, E.V.M.; Ribeiro, J.F.R.; Rocha, J.R.; Rosini, F.; Saidel, M.E. Molecular design, synthesis and trypanocidal activity of dipeptidyl nitriles as cruzain inhibitors. PLoS Negl. Trop. Dis., 2015, 7, e0003916.
[19]
Burtoloso, A.C.B.; Albuquerque, S.; Fuber, M.; Gomes, J.C.; Gonçalez, C.; Kenny, P.W.; Leitão, A.; Montanari, C.A.; Quilles, J.C.J.; Ribeiro, J.F.R.; Rocha, J.R. Anti-trypanosomal activity of non-peptidic nitrile-based cysteine protease inhibitors. PLoS Negl. Trop. Dis., 2017, 2, e0005343.
[20]
Santoro, A.L.; Carrilho, E.; Lanças, F.M.; Montanari, C.A. Quantitative structure-retention relationships of flavonoids unraveled by immobilized artificial membrane chromatography. Eur. J. Pharm. Sci., 2016, 88, 147-157.
[21]
Murray, E.J.; Grisanti, M.S.; Bentley, G.V.; Murray, S.S. E64d, a membrane-permeable cysteine protease inhibitor, attenuates the effects of parathyroid hormone on osteoblasts in vitro. Metabolism, 1997, 46, 1090-1094.
[22]
Ng, K.W. Potential role of odanacatib in the treatment of osteoporosis. Clin. Interv. Aging, 2012, 7, 235-247.
[23]
Montanari, M.L.C.; Montanari, C.A.; Piló-Veloso, D.; Cass, Q.B. Estimation of the RP-HPLC lipophilicity parameters Log K′, and log KW, a comparison with the hydrophobicity index ϕ0. J. Liq. Chrom. Rel. Technol., 1997, 11, 1703-1715.
[24]
Rutkowska, E.; Pajak, K.; Józwiak, K. Lipophilicity and methods of determination and its role in medicinal chemistry. Acta Pol. Pharm., 2013, 1, 3-18.
[25]
Bone, H.G.; Dempster, D.W.; Eisman, J.A.; Greenspan, S.L.; McClung, M.R.; Nakumura, T.; Papapoulos, S.; Shih, W.J.; Rybak-Feiglin, A.; Santora, A.C.; Verbuggen, N.; Leung, A.T.; Lombardi, A. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos. Int., 2015, 26, 699-712.
[26]
Gagnon, A.; Amad, M.H.; Bonneau, P.R.; Coulombe, R.; DeRoy, P.L.; Doyon, L.; Duan, J.; Garneau, M.; Guse, I.; Jakalian, A.I.; Jolicoeur, E.; Landry, S.; Malenfant, E.; Simonneau, B.; Yoakim, C. Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wide type and K103N/Y181C double mutant reserve transcriptases. Bioorg. Med. Chem. Lett., 2007, 17, 4437-4441.
[27]
Franken, N.A.P.; Rodermond, H.M.; Stap, J.; Haveman, J.; Bree, C.V. Clonogenic assay of cells in vitro. Nat. Protoc., 2006, 5, 2315-2319.
[28]
Song, L.; Chang, J.; Li, Z. A serine protease extracted from Trichosanthes kirilowii induces apoptosis via the PI3K/AKT-mediated mitochondrial pathway in human colorectal adenocarcinoma cells. Food Funct., 2016, 2, 843-854.
[29]
Martin, A.C.B.M.; Cardoso, A.C.R.; Araujo, H.S.S.; Cominetti, M.R. Recombinant disintegrin domain of human ADAM9 inhibits migration and invasion of DU145 prostate tumor cells. Cell Adhes. Migr., 2015, 4, 1-7.
[30]
Katt, M.E.; Placone, A.L.; Wong, A.D.; Xu, Z.S.; Searson, P.C. In vitro tumor models: Advantages, disadvantages, variables, and selecting the right platform. Front. Bioeng. Biotechnol., 2016, 4, 12.
[31]
Mohamed, M.M.; Sloane, B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer, 2006, 10, 764-775.
[32]
Lankelma, J.M.; Voorend, D.M.; Barwari, T.; Koetsveld, J.; Van der Spek, A.H.; De Porto, A.P.N.A.; Rooijen, G.V.; Noorden, C.J.F. Cathepsin L, target in cancer treatment? Life Sci., 2010, 86, 225-233.
[33]
Colella, R.; Jackson, T.; Goodwyn, E. Matrigel invasion by the prostate cancer cell lines, PC3 and DU145, and cathepsin L+B activity. Biotech. Histochem., 2006, 79, 121-127.
[34]
Mehlen, P.; Puisieux, A. Metastasis: A question of life and death. Nat. Rev. Cancer, 2006, 6, 449-458.
[35]
Tumura, K. Development of cell-cycle checkpoint therapy for solid tumors. Jpn. J. Clin. Med., 2015, 12, 1097-1102.
[36]
Sudhan, D.R.; Siemann, D.W. Cathepsin L targeting in cancer treatment. Pharmacol. Ther., 2015, 155, 105-116.
[37]
Goulet, B.; Nepveu, A. Development of cell-cycle checkpoint therapy for solid tumors. Cell Cycle, 2004, 8, 986-989.
[38]
Sant, S.; Johnston, P.A. The production of 3D tumor spheroids for cancer drug discovery. Drug Discov. Today. Technol., 2017, 23, 27-36.
[39]
Shelper, T.B.; Lovitt, C.J.; Avery, V.M. Assessing drug efficacy in a miniaturized pancreatic cancer in vitro 3d cell culture model. Assay Drug Dev. Technol., 2016, 7, 367-380.
[40]
Demchik, L.L.; Sameni, M.; Nelson, K.; Mikkelsen, T.; Sloane, B.F. Cathepsin B and glioma invasion. Int. J. Dev. Neurosci., 1999, 17, 483-494.
[41]
Lakka, S.S.; Gondi, C.S.; Yanamandra, N.; Olivero, W.C.; Dinh, D.H.; Gujrati, M.; Rao, J.S. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene, 2004, 23, 4681-4689.
[42]
Cartledge, D.M.; Colella, R.; Glazewski, L.; Lu, G.; Mason, R.W. Inhibitors of cathepsins B and L induce autophagy and cell death in neuroblastoma cells. Invest. New Drugs, 2013, 31, 20-29.
[43]
Sabeh, F.; Shimizu-Hirota, R.; Weiss, S.J. Protease-dependent versus-independent cancer cell invasion programs: Three-dimensional amoeboid movement revisited. J. Cell Biol., 2009, 185, 11-19.
[44]
Li, F.; Gonzalez, F.J.; Ma, X. LC-MS-based metabolomics in profiling of drug metabolism and bioactivation. Acta Pharm. Sin. B, 2012, 2, 118-125.
[45]
Blair, I.A.; Tilve, A. Analysis of anticancer drugs and their metabolites by mass spectrometry. Curr. Drug Metab., 2002, 3, 463-480.
[46]
Borowa-Mazgaj, B.; Mróz, A.; Augustin, E.; Paluszkiewicz, E.; Mazerska, Z. The overexpression of CPR and P450 3A4 in pancreatic cancer cells changes the metabolic profile and increases the cytotoxicity and pro-apoptotic activity of acridine antitumor agent, C-1748. Biochem. Pharmacol., 2017, 142, 21-38.
[47]
Cooke, M.S.; Evans, M.D.; Dizdaroglu, M.; Lunec, J. Oxidative DNA damage: Mechanisms, mutation, and disease. FASEB J., 2003, 10, 1195-1214.
55
5